HC Wainwright Reaffirms “Neutral” Rating for Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “neutral” rating restated by equities researchers at HC Wainwright in a research note issued on Monday,Benzinga reports. HC Wainwright also issued estimates for Assembly Biosciences’ FY2029 earnings at ($12.58) EPS.

Assembly Biosciences Price Performance

Shares of Assembly Biosciences stock opened at $11.42 on Monday. Assembly Biosciences has a 1 year low of $10.27 and a 1 year high of $19.93. The company has a market capitalization of $72.59 million, a price-to-earnings ratio of -1.70 and a beta of 0.62. The business has a fifty day simple moving average of $12.77 and a two-hundred day simple moving average of $15.05.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.75) by $0.18. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. The company had revenue of $7.36 million during the quarter, compared to analysts’ expectations of $7.05 million. As a group, equities analysts anticipate that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Assembly Biosciences news, Director Michael Houghton purchased 3,202 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average cost of $15.61 per share, for a total transaction of $49,983.22. Following the completion of the purchase, the director now owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.10% of the company’s stock.

Institutional Trading of Assembly Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of ASMB. Gilead Sciences Inc. acquired a new position in shares of Assembly Biosciences during the 4th quarter worth approximately $34,865,000. Renaissance Technologies LLC boosted its stake in shares of Assembly Biosciences by 44.3% in the fourth quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company’s stock valued at $1,495,000 after buying an additional 29,087 shares during the period. Peapod Lane Capital LLC bought a new stake in shares of Assembly Biosciences in the fourth quarter valued at approximately $994,000. B Group Inc. acquired a new stake in Assembly Biosciences during the fourth quarter worth approximately $799,000. Finally, Monimus Capital Management LP bought a new position in Assembly Biosciences during the 4th quarter worth $664,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.